Bivalent Omicron BA.4/BA.5 BNT162b2 Vaccine in 6-Month- to <12-Year-Olds.

Lawrence D SherJustice K Boakye-AppiahSungeen HillEmily WassermanXia XuYvonne MaldonadoEmmanuel B WalterFlor Muñoz RivasGrant C PaulsenJanet A EnglundKawsar R TalaatElizabeth D BarnettSatoshi KamidaniShelly SendersEric A F SimõesKelly BelangerVrunda ParikhHua MaXingbin WangClaire LuDavid CooperKenneth KouryAnnaliesa S AndersonÖzlem TüreciUğur ŞahinKena A SwansonWilliam C GruberAlejandra GurtmanNicholas KitchinCharu Sabharwal

Published in: Journal of the Pediatric Infectious Diseases Society (2024)

These safety and immunogenicity data support a favorable benefit-risk profile for a variant-adapted BNT162b2 in children <12 years old.

Keyphrases

young adults
electronic health record
big data
machine learning
data analysis